全文获取类型
收费全文 | 6401篇 |
免费 | 272篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 79篇 |
儿科学 | 117篇 |
妇产科学 | 311篇 |
基础医学 | 643篇 |
口腔科学 | 206篇 |
临床医学 | 493篇 |
内科学 | 1699篇 |
皮肤病学 | 86篇 |
神经病学 | 371篇 |
特种医学 | 324篇 |
外科学 | 1178篇 |
综合类 | 25篇 |
一般理论 | 1篇 |
预防医学 | 207篇 |
眼科学 | 339篇 |
药学 | 238篇 |
中国医学 | 4篇 |
肿瘤学 | 432篇 |
出版年
2024年 | 4篇 |
2023年 | 67篇 |
2022年 | 112篇 |
2021年 | 195篇 |
2020年 | 116篇 |
2019年 | 175篇 |
2018年 | 225篇 |
2017年 | 118篇 |
2016年 | 167篇 |
2015年 | 164篇 |
2014年 | 254篇 |
2013年 | 365篇 |
2012年 | 497篇 |
2011年 | 586篇 |
2010年 | 361篇 |
2009年 | 356篇 |
2008年 | 489篇 |
2007年 | 547篇 |
2006年 | 497篇 |
2005年 | 440篇 |
2004年 | 339篇 |
2003年 | 260篇 |
2002年 | 197篇 |
2001年 | 35篇 |
2000年 | 16篇 |
1999年 | 15篇 |
1998年 | 37篇 |
1997年 | 20篇 |
1996年 | 22篇 |
1995年 | 17篇 |
1994年 | 9篇 |
1993年 | 5篇 |
1992年 | 9篇 |
1990年 | 2篇 |
1989年 | 7篇 |
1988年 | 2篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1982年 | 2篇 |
1981年 | 2篇 |
1980年 | 2篇 |
1978年 | 1篇 |
1977年 | 1篇 |
排序方式: 共有6753条查询结果,搜索用时 203 毫秒
151.
152.
Joerg Meyle Priscila Casado Ioannis Fourmousis Purnima Kumar Marc Quirynen Giovanni E. Salvi 《International dental journal》2019,69(Z2):3-6
For decades, oral implants have been used successfully for the replacement of missing teeth. Nevertheless, peri‐implant diseases have become an increasingly important issue in daily practice. In this working group, the prevalence of peri‐implant mucositis and peri‐implantitis, as well as different general risk factors and their impact on the onset and progression of peri‐implant diseases, were discussed based on reviews reflecting the current state of evidence. The influence of smoking on the peri‐implant bone‐healing process and its association with peri‐implantitis has been explored in the current literature, demonstrating that smoking is an important risk indicator for the development of peri‐implantitis and implant loss. Compared with non‐smokers, smokers have a higher potential for pathological peri‐implant bone loss, which is also influenced by poor oral hygiene. Despite the fact that a growing number of genetic polymorphisms have been identified and related to periodontal diseases, there are still no genetic patterns that could act as adjuncts to clinical diagnostics in order to identify patients at higher risk of peri‐implant diseases. Long‐term medications, such as bisphosphonate therapy (> 3 years), may have an impact on implant loss. A higher incidence of implant failure was reported in patients using selective serotonin reuptake inhibitors in anti‐depression therapy. Alcoholism (defined as more than 5 units a day) has been associated with implant loss in retrospective and case–control studies, as well as in animal studies. 相似文献
153.
Stefan Renvert Hideaki Hirooka Ioannis Polyzois Anastasia Kelekis‐Cholakis Hom‐Lay Wang 《International dental journal》2019,69(Z2):12-17
The following consensus report is based on four background reviews. The frequency of maintenance visits is based on patient risk indicators, homecare compliance and prosthetic design. Generally, a 6‐month visit interval or shorter is preferred. At these visits, peri‐implant probing, assessment of bleeding on probing and, if warranted, a radiographic examination is performed. Diagnosis of peri‐implant mucositis requires: (i) bleeding or suppuration on gentle probing with or without increased probing depth compared with previous examinations; and (ii) no bone loss beyond crestal bone level changes resulting from initial bone remodelling. Diagnosis of peri‐implantitis requires: (i) bleeding and/or suppuration on gentle probing; (ii) an increased probing depth compared with previous examinations; and (iii) bone loss beyond crestal bone level changes resulting from initial bone remodelling. If diagnosis of disease is established, the inflammation should be resolved. Non‐surgical therapy is always the first choice. Access and motivation for optimal oral hygiene are key. The patient should have a course of mechanical therapy and, if a smoker, be encouraged not to smoke. Non‐surgical mechanical therapy and oral hygiene reinforcement are useful in treating peri‐implant mucositis. Power‐driven subgingival air‐polishing devices, Er: YAG lasers, metal curettes or ultrasonic curettes with or without plastic sleeves can be used to treat peri‐implantitis. Such treatment usually provides clinical improvements such as reduced bleeding tendency, and in some cases a pocket‐depth reduction of ≤ 1 mm. In advanced cases, however, complete resolution of the disease is unlikely. 相似文献
154.
Irini Flouri Theodora E. Markatseli Paraskevi V. Voulgari Kyriaki A. Boki Ioannis Papadopoulos Loukas Settas Dimitrios Zisopoulos Fotini N. Skopouli Alexios Iliopoulos George K. Bertsias Pierre Geborek Alexandros A. Drosos Dimitrios T. Boumpas Prodromos Sidiropoulos 《Seminars in arthritis and rheumatism》2014
Objective
To compare effectiveness, drug survival, and safety between infliximab, adalimumab, and etanercept, in a nationwide cohort of rheumatoid arthritis (RA) patients.Methods
This study is a prospective cohort study of 1208 active RA patients. Effectiveness, drug survival, and serious adverse events during entire follow-up (median 2.9 years) were monitored.Results
EULAR and CDAI responses were comparable between the three agents (EULAR good/moderate responses at 12 months ranged 76–79%). At 12 months, 15–23% achieved remission. For adalimumab and etanercept, adjusted hazard rate (HR) for EULAR/ACR remission (reference: infliximab) was 2.7 and 2.1 (95% confidence interval was 1.7–4.1 and 1.3–3.4, respectively); males (HR 1.6; 1.1–2.4), use of glucocorticoids (HR 2.0; 1.3–3.0), and swollen joint count >7 (HR 0.36; 0.24–0.55) were independent predictors. Five-year drug survival was 31%, 43%, and 49% for infliximab, adalimumab, and etanercept, respectively (p = 0.010). Infliximab was associated with significantly more withdrawals due to adverse events. Disease activity, CRP, and use of glucocorticoids predicted efficacy-related drug survival; age, use of methotrexate, and prior DMARDs failures predicted safety-related survival. Risk for serious infections was lower with adalimumab (odds ratio [OR] 0.62; 0.38–1.00) or etanercept (OR 0.39; 0.21–0.72) than infliximab, independent of the effects of age (OR 1.65; 1.37–2.00 per 10 years), tender joint count >10 (OR 1.86; 1.21–2.86), and glucocorticoids >35 mg/week (OR 1.83; 1.12–2.99).Conclusions
Response rates were comparable among anti-TNF agents. Overall, 5-year drug survival was below 50%, with infliximab demonstrating increased safety-related discontinuations. Remission rates are low in clinical practice. Strategies to increase effectiveness and long-term survival of anti-TNF agents in RA are needed. 相似文献155.
Kahal Hassan Kyrou Ioannis Uthman Olalekan A. Brown Anna Johnson Samantha Wall Peter D. H. Metcalfe Andrew Parr David G. Tahrani Abd A. Randeva Harpal S. 《Sleep & breathing》2020,24(1):339-350
Sleep and Breathing - Obesity is a common risk factor for polycystic ovary syndrome (PCOS) and obstructive sleep apnoea (OSA). Both PCOS and OSA are associated with increased risk of type 2... 相似文献
156.
Ioannis Bellos Vasilios Pergialiotis Dimitrios Loutradis Georgios Daskalakis 《Journal of clinical hypertension (Greenwich, Conn.)》2020,22(5):826-834
This meta‐analysis aims to compare serum uric acid levels among preeclamptic and healthy pregnant women across the various trimesters and provide a summary of the effect size of this biomarker in predicting adverse pregnancy outcomes. MEDLINE, Scopus, CENTRAL, Clinicaltrials.gov, and Google Scholar databases were systematically searched from inception. Observational studies were held eligible if they reported serum uric acid among preeclamptic and healthy pregnant women. Meta‐analysis was conducted regarding uric acid concentration, diagnostic accuracy, and association with perinatal outcomes. The credibility of evidence was appraised using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. The analysis included 196 studies, comprising 39 540 women. Preeclampsia was associated with significantly elevated uric acid levels during the 1st (mean difference [MD]: 0.21 mg/dL, 95% confidence intervals [CI]: 0.06‐0.35) trimester, 2nd (MD: 1.41 mg/dL, 95% CI: 0.78‐2.05) trimester, and 3rd (MD: 2.26 mg/dL, 95% CI: 2.12‐2.40) trimester. Higher uric acid was estimated for severe preeclampsia, eclampsia, and hemolysis, elevated liver enzymes, low platelet syndrome. The sensitivity for adverse perinatal outcome prediction ranged from 67.3% to 82.7% and the specificity from 47.7% to 70.7%. In conclusion, it is suggested that serum uric acid levels are increased in preeclampsia and can be used to predict disease severity and pregnancy complications. Future prospective studies should verify these outcomes, assess the optimal cutoffs, and incorporate uric acid to combined predicting models. 相似文献
157.
Ioannis Papaconstantinou Evanthia Zampeli Dionysios Dellaportas Charalambos Giannopoulos Maria Sotiropoulou George Polymeneas Giorgos Bamias Spyros Michopoulos 《Clinical journal of gastroenterology》2014,7(2):132-135
Pouchitis occurs in up to one half of patients after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). Cytomegalovirus (CMV) and Clostridium difficile are among the commonest secondary identifiable etiologies. A 17-year-old male with ulcerative colitis underwent IPAA due to refractory disease. Nine months later he experienced bloody diarrhea and fever. Laboratory testing and endoscopy confirmed pouch inflammation. Testing for C. difficile toxins A and B was positive. Histology revealed affluent inclusion bodies and immunohistochemistry detected reactivity against CMV protein. Treatment with metronidazole and vancomycin offered partial improvement, whereas the addition of gancyclovir led to a successful recovery. One month after completion of treatment symptoms recurred. Repeat testing precluded an identifiable infectious cause and the diagnosis of idiopathic chronic pouchitis was established. The patient is currently on maintenance treatment with the probiotic compound VSL#3. 相似文献
158.
159.